The Filing Desk

AbbVie

ABBV · NYSE · Health Care · Financials, fiscal 2016 to 2025

ABBV · Last close · November 19, 2026
$283.54
Value AbbVie yourself

AbbVie's revenue rose 8.6% to $61.2 billion in fiscal 2025. Its operating margin was 24.6%, up from 16.2% a year earlier. Free cash flow was $17.8 billion, down 0.1%. It paid out $12.6 billion in dividends and buybacks, 71% of free cash flow.

AbbVie Inc. Latest fiscal year ended December 31, 2025 10-K filed February 20, 2026 · 0001551152-26-000008 Updated
Revenue
$61.2B
8.6%
Operating margin
24.6%
8.4 pts
Net income
$4.2B
1.2%
Free cash flow
$17.8B
0.1%
Return on capital
15.7%
0.7 pts
Market cap
$502.4B
Nov 19 close
P/E
48.8x
On $5.81 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. AbbVie's shareholders' equity fell close to zero and then below it in 2025, so return on equity and debt to equity are left blank for those years.

Charts show fiscal years, from the 10-K filings.

What AbbVie does

AbbVie researches, makes and sells prescription medicines and related products worldwide. Its main areas are immunology (Skyrizi, Rinvoq and Humira, used for autoimmune diseases), neuroscience (including Vraylar, Botox Therapeutic, and migraine and Parkinson's treatments), oncology (blood cancers and other cancers), and aesthetics (Botox Cosmetic and Juvederm). It also sells eye care products and treatments for hepatitis C and digestive conditions.

AbbVie reports as a single business segment. It makes money by selling its medicines. In the United States it sells mainly to three wholesale distributors, McKesson, Cardinal Health and Cencora. No single wholesaler accounted for more than 43% of its 2025 gross revenues in the United States. Outside the United States it sells to wholesalers and distributors and to government payers. Some aesthetic products are sold directly to doctors and other licensed providers. It also markets to doctors, hospitals, managed care providers and government agencies.

AbbVie says it competes with other drug and biotech companies, and that generic and biosimilar copies of branded drugs add pressure on products without patent protection. It says Humira already faces direct biosimilar competition around the world. AbbVie became an independent public company in 2013, when Abbott Laboratories distributed AbbVie's shares to its own shareholders.

Its biggest risks, as it describes them

  • Losing patent protection on major products, and the competition from generics and biosimilars that follows.
  • Research and development that may not produce new products that can be sold successfully.
  • Pricing pressure from governments, rebate programs, and pharmacy benefit managers that influence access to its drugs.
  • Safety or effectiveness problems with its products, and product liability claims.
  • Manufacturing problems, or an interruption in supplies from single-source suppliers.
From AbbVie's annual report on Form 10-K, filed February 20, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share fell 4.7% a year and net income 3.7% a year, as new shares raised the share count by 9% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments9.89.212.85.65.3
Debt incl. finance leases76.063.259.366.967.0
Net debt (negative means net cash)66.253.946.561.361.8
Net debt to EBITDA2.5x2.0x2.2x3.5x2.7x
Debt to equity4.9x3.7x5.7x——
Interest coverage7.4x8.1x5.7x3.2x5.2x
Current ratio0.8x1.0x0.9x0.7x0.7x
Quick ratio0.7x0.8x0.8x0.6x0.6x
US$ billions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, billions

Projections

Project AbbVie's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What AbbVie says to expect

  • Full year 2026: adjusted diluted EPSAbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2026.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed October 30, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought AbbVie shares on the open market, and 4 insiders sold $30.8 million, $9.5 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 9, 2026Jeffrey Ryan StewartEVP, Chief Commercial OfficerSold40,619$293.60$11.9 millionForm 4
Aug 14, 2026Nicholas DonoghoeEVP, Chief Bus/strat OfficerSold32,710$250.00$8.2 millionForm 4
Mar 4, 2026David Ryan PurdueSVP, ControllerSold5,230$233.56$1.2 millionForm 4
Mar 2, 2026Perry C SiatisEVP, GC and SecretarySold plan18,668$234.39$4.4 millionForm 4
Feb 25, 2026Perry C SiatisEVP, GC and SecretarySold plan22,381$230.00$5.1 millionForm 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score5 of 96 of 97 of 9
Rule of 4034.2%35.4%37.7%
Altman Z''0.46−0.35−0.34
Accruals ratio−13.1%−10.8%−11.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassFailFail
Current ratio roseFailFailPass
Share count didn't risePassPassPass
Gross margin roseFailPassPass
Revenue rose relative to assetsFailPassPass
F-score5 of 96 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put AbbVie side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
AbbVieFY258.6%24.6%29.1%15.7%2.7x7
Johnson & JohnsonFY256.0%—20.9%28.6%0.7x4Compare
PfizerFY25−1.6%—14.5%7.2%3.2x6Compare
ModernaFY25−39.9%−158.1%−106.2%−65.4%—2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue25.628.232.833.345.856.258.154.356.361.2
Revenue growth12.2%10.1%16.1%1.6%37.7%22.7%3.3%−6.4%3.7%8.6%
Gross profit19.821.225.025.830.438.840.633.939.443.0
Research and development4.45.010.36.46.46.96.57.712.89.1
Operating income9.39.56.413.011.417.918.112.89.115.1
Net income6.05.35.77.94.611.511.84.94.34.2
Diluted EPS (US$)3.633.303.665.282.726.456.632.722.392.36
Diluted shares (millions)1,6311,6031,5461,4841,6731,7771,7781,7731,7731,773
Cash flow
Cash from operations7.010.013.413.317.622.824.922.818.819.0
Capital expenditure0.50.50.60.60.80.80.70.81.01.2
Free cash flow6.69.412.812.816.822.024.222.117.817.8
Dividends paid3.74.15.66.47.79.310.010.511.011.7
Share buybacks6.01.412.00.61.00.91.52.01.71.0
Acquisitions2.50.00.00.038.30.50.30.017.50.2
Stock-based compensation0.40.40.40.40.80.70.70.70.91.0
Balance sheet at fiscal year end
Cash and short-term investments6.49.88.139.98.59.89.212.85.65.3
Debt incl. finance leases36.837.440.367.385.076.063.259.366.967.0
Total assets66.170.859.489.1150.6146.5138.8134.7135.2134.0
Total liabilities61.565.767.897.3137.5131.1121.5124.3131.8137.2
Shareholders' equity4.65.1−8.4−8.213.115.417.310.43.3−3.3
Margins and ratios
Gross margin77.2%75.0%76.4%77.6%66.4%69.0%70.0%62.4%70.0%70.2%
Operating margin36.4%33.8%19.5%39.0%24.8%31.9%31.2%23.5%16.2%24.6%
Net margin23.2%18.8%17.4%23.7%10.1%20.5%20.4%8.9%7.6%6.9%
Free cash flow margin25.6%33.4%39.0%38.4%36.7%39.1%41.8%40.6%31.6%29.1%
Rule of 40 (growth + FCF margin)37.8%43.5%55.1%40.0%74.3%61.8%45.1%34.2%35.4%37.7%
Return on capital22.6%19.4%22.6%56.5%20.9%18.6%20.8%15.5%15.0%15.7%
Return on equity138.8%109.1%———81.0%72.5%35.2%62.5%—
Return on assets10.0%7.8%8.7%10.6%3.9%7.8%8.3%3.6%3.2%3.1%
Net debt to EBITDA2.9x2.5x4.0x1.8x4.3x2.5x2.0x2.2x3.5x2.7x
US$ billions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: AbbVie's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with AbbVie.